Importance Metastatic hormone-sensitive prostate cancer is currently an incurable disease.
Despite a high response rate to androgen-deprivation therapy, most cases progress to …

The treatment landscape of advanced prostate cancer has widely expanded over the past
years with androgen receptor signaling inhibitors (ARSIs) and taxane chemotherapy moving …

Importance Despite evidence demonstrating an overall survival benefit with up-front
hormone therapy in addition to established synergy between hormone therapy and …

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …

Background: The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH)
antagonists compared with GnRH agonists in men with prostate cancer and known …

Importance Preferential delivery of docetaxel to tumors by prostate-specific membrane
antigen (PSMA)–targeted nanoparticles is clinically effective, and the selective reduction of …

Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in
STAMPEDE, a multiarm, multistage platform trial in men starting long‐term hormone therapy …

Adaptive designs (ADs) allow pre-planned changes to an ongoing trial without
compromising the validity of conclusions and it is essential to distinguish pre-planned from …

Objective To estimate the association between oncologists' receipt of payments from the
pharmaceutical industry and delivery of non-recommended or low value interventions …

Importance Recently, life-prolonging treatments for patients with advanced prostate cancer
have been introduced in clinical practice. Objective To investigate if the introduction of …